Humidifier lung is a subtype of hypersensitivity pneumonitis (HP) triggered by repeated exposure to an antigen. The mainstay of therapy is antigen avoidance. A Caucasian male in his 30s presented with a six-month history of progressively worsening dyspnea and cough. On presentation, he was hypoxic on room air. Laboratory work was significant for a leukocytosis and a CT angiogram of the chest demonstrated diffuse ill-defined ground-glass opacities in both lungs. The patient was admitted for community-acquired pneumonia, but his symptoms worsened, so additional infectious and rheumatological work-up was obtained. History revealed the patient used a home humidifier daily for the past year. Cultures obtained from the humidifier grew Lung biopsy demonstrated diffuse lymphoplasmacytic infiltrates and poorly formed granulomas consistent with HP. The humidifier was removed from the individual's home, and he was treated with systemic steroids, with complete resolution of his symptoms. Obtaining a detailed history plays a pivotal role in diagnosing HP.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11521319 | PMC |
http://dx.doi.org/10.7759/cureus.70448 | DOI Listing |
German recommendations for the diagnosis of hypersensitivity pneumonitis (HP), also known as extrinsic allergic alveolitis (EAA), were last published in 2007 [1]. The current S2k Guideline for the Diagnosis and Treatment of Hypersensitivity Pneumonitis (HP) replaces these diagnostic recommendations. They were supplemented by the aspect of chronic, and in particular of the chronic fibrotic phenotype of HP, and also, as first HP guideline, include treatment recommendations.
View Article and Find Full Text PDFCureus
December 2024
Pulmonology, Jinnah Postgraduate Medical Centre, Karachi, PAK.
Background Interstitial lung diseases (ILDs) are a group of non-infectious diseases characterized by interstitial inflammation and fibrosis on histological examination. Gastroesophageal reflux disease (GERD) is common in this patient population, but whether there is a causal or coincidental relationship is not yet clear. It still remains unsettled how to diagnose GERD, and the role of different treatment modalities for GERD, in these lung disorders.
View Article and Find Full Text PDFBiomolecules
January 2025
Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo 113-8421, Japan.
Diffuse interstitial lung diseases (ILD) include conditions with identifiable causes such as chronic eosinophilic pneumonia (CEP), sarcoidosis (SAR), chronic hypersensitivity pneumonitis (CHP), and connective tissue disease-associated interstitial pneumonia (CTD), as well as idiopathic interstitial pneumonia (IIP) of unknown origin. In non-IIP diffuse lung diseases, bronchoalveolar lavage (BAL) fluid appearance is diagnostic. This study examines lymphocyte subsets in BAL fluid and peripheral blood of 56 patients with diffuse ILD, excluding idiopathic pulmonary fibrosis (IPF), who underwent BAL for diagnostic purposes.
View Article and Find Full Text PDFActa Biochim Biophys Sin (Shanghai)
January 2025
Department of Respiratory and Critical Care Medicine, First People's Hospital of Kashi, Kashi 844000, China.
Hypersensitivity pneumonitis (HP), including pigeon breeder's lung (PBL), often progresses from acute inflammation to fibrosis, impairing lung function and limiting targeted therapeutic strategies. Mechanistic studies on PBL progression are limited by the lack of preclinical animal models and a predominant focus on patient data. This study explores the immunopathological characteristics of all stages of PBL in mice and evaluates the therapeutic potential of human umbilical cord-derived mesenchymal stem cells (UC-MSCs) during the non-fibrotic stage.
View Article and Find Full Text PDFJ Thorac Dis
December 2024
Division of Thoracic Surgery, University Hospital of Munich, LMU, Munich, Germany.
Background: Lung transplantation (LuTX) can be the last resort for patients with end-stage lung diseases. In the last decades, improvements were implemented in transplant medicine, from immunosuppression throughout preservation of the donor organ to enhance lung allograft survival. This retrospective study aims to illustrate the development of the LuTX-program at the University Hospital of Munich, LMU, Munich, Germany, since its launch in 1990 by depicting and comparing postoperative outcome.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!